Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Q3 2025 value amounting to -$517000.0.

  • Vanda Pharmaceuticals' Cash from Financing Activities changed N/A to -$517000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year change of. This contributed to the annual value of -$155000.0 for FY2024, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Vanda Pharmaceuticals' Cash from Financing Activities is -$517000.0.
  • Vanda Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $1.8 million during Q1 2021, with a 5-year trough of -$1.3 million in Q1 2025.
  • In the last 4 years, Vanda Pharmaceuticals' Cash from Financing Activities had a median value of $125000.0 in 2022 and averaged $169363.6.
  • In the last 5 years, Vanda Pharmaceuticals' Cash from Financing Activities soared by 28601.25% in 2021 and then plummeted by 9892.18% in 2022.
  • Quarter analysis of 4 years shows Vanda Pharmaceuticals' Cash from Financing Activities stood at $1.0 million in 2021, then tumbled by 41.88% to $605000.0 in 2022, then crashed by 125.62% to -$155000.0 in 2024, then tumbled by 233.55% to -$517000.0 in 2025.
  • Its Cash from Financing Activities was -$517000.0 in Q3 2025, compared to -$425000.0 in Q2 2025 and -$1.3 million in Q1 2025.